These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 12719275)
1. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Pelat M; Dessy C; Massion P; Desager JP; Feron O; Balligand JL Circulation; 2003 May; 107(19):2480-6. PubMed ID: 12719275 [TBL] [Abstract][Full Text] [Related]
2. Control of blood pressure variability in caveolin-1-deficient mice: role of nitric oxide identified in vivo through spectral analysis. Desjardins F; Lobysheva I; Pelat M; Gallez B; Feron O; Dessy C; Balligand JL Cardiovasc Res; 2008 Aug; 79(3):527-36. PubMed ID: 18349137 [TBL] [Abstract][Full Text] [Related]
3. Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level. Bulhak AA; Gourine AV; Gonon AT; Sjöquist PO; Valen G; Pernow J Acta Physiol Scand; 2005 Feb; 183(2):151-9. PubMed ID: 15676056 [TBL] [Abstract][Full Text] [Related]
4. Aortic eNOS expression and phosphorylation in Apo-E knockout mice: differing effects of rapamycin and simvastatin. Naoum JJ; Zhang S; Woodside KJ; Song W; Guo Q; Belalcazar LM; Hunter GC Surgery; 2004 Aug; 136(2):323-8. PubMed ID: 15300198 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of P104L mutant caveolin-3 in mice develops hypertrophic cardiomyopathy with enhanced contractility in association with increased endothelial nitric oxide synthase activity. Ohsawa Y; Toko H; Katsura M; Morimoto K; Yamada H; Ichikawa Y; Murakami T; Ohkuma S; Komuro I; Sunada Y Hum Mol Genet; 2004 Jan; 13(2):151-7. PubMed ID: 14645200 [TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice. Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361 [TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. Desjardins F; Sekkali B; Verreth W; Pelat M; De Keyzer D; Mertens A; Smith G; Herregods MC; Holvoet P; Balligand JL Eur Heart J; 2008 Jan; 29(1):128-37. PubMed ID: 18063594 [TBL] [Abstract][Full Text] [Related]
9. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Custodis F; Baumhäkel M; Schlimmer N; List F; Gensch C; Böhm M; Laufs U Circulation; 2008 May; 117(18):2377-87. PubMed ID: 18443241 [TBL] [Abstract][Full Text] [Related]
10. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Di Napoli P; Taccardi AA; Grilli A; De Lutiis MA; Barsotti A; Felaco M; De Caterina R Cardiovasc Res; 2005 Jun; 66(3):462-71. PubMed ID: 15914111 [TBL] [Abstract][Full Text] [Related]
11. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Ii M; Nishimura H; Kusano KF; Qin G; Yoon YS; Wecker A; Asahara T; Losordo DW Circulation; 2005 Jul; 112(1):93-102. PubMed ID: 15983249 [TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet. Famer D; Crisby M Neurosci Lett; 2007 May; 419(1):68-73. PubMed ID: 17433542 [TBL] [Abstract][Full Text] [Related]
13. Morphological and functional alterations of the cochlea in apolipoprotein E gene deficient mice. Guo Y; Zhang C; Du X; Nair U; Yoo TJ Hear Res; 2005 Oct; 208(1-2):54-67. PubMed ID: 16051453 [TBL] [Abstract][Full Text] [Related]